论文部分内容阅读
从目前已研究出的抗多种肿瘤的单克隆抗体来看,其中已有不少可以用来测定肿瘤患者血清、胸腹水或胃液中的肿瘤相关抗原,并显示出一定的诊断价值。国内已有不少学者认为,胃液中胃癌的肿瘤相关抗原(MG-Ags)浓度的动态变化可以成为一项判定患者病情进展,治疗效果和预后变化的指标。本研究试图通过对血清中胃癌MG-Aes浓度的测定与胃肠道恶性肿瘤预后变化,疗效评定、病情进展的相关性作一初步探讨,现报告如下。
From the point of view of the monoclonal antibodies that have been studied against a variety of tumors, many of them can be used to determine tumor-associated antigens in serum, pleural effusion, ascites, or gastric juice in patients with tumors, and have shown some diagnostic value. Many domestic scholars believe that the dynamic changes of gastric cancer-associated tumor-associated antigen (MG-Ags) concentration can be an indicator to determine the patient’s disease progression, treatment effectiveness and prognosis. This study attempts to make a preliminary study of the relationship between the determination of gastric cancer MG-Aes concentration in serum and the prognosis of gastrointestinal cancer, efficacy evaluation, and disease progression. The report is as follows.